Altimmune Inc (ALT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Altimmune Inc (ALT) has a cash flow conversion efficiency ratio of -0.086x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-19.45 Million) by net assets ($224.89 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ALT net asset quality index to measure how much of total assets are equity-financed.
Altimmune Inc - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how Altimmune Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Altimmune Inc cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
Altimmune Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Altimmune Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Doright Co.Ltd.
SHE:300950
|
-0.007x |
|
Emeco Holdings Ltd
AU:EHL
|
0.189x |
|
Ningxia Younglight Chemicals Co Ltd
SHE:000635
|
0.008x |
|
STP&I Public Company Limited
BK:STPI
|
0.040x |
|
Shenzhen HeKeda Precision Cleaning Equipment Co Ltd
SHE:002816
|
-0.058x |
|
Ipd Group Ltd
AU:IPG
|
0.062x |
|
FuJian YanJing HuiQuan Brewery Co Ltd
SHG:600573
|
0.057x |
|
ECARX Holdings Inc. Class A Ordinary shares
NASDAQ:ECX
|
-0.141x |
Annual Cash Flow Conversion Efficiency for Altimmune Inc (2005–2025)
The table below shows the annual cash flow conversion efficiency of Altimmune Inc from 2005 to 2025. For the full company profile with market capitalisation and key ratios, see ALT stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $224.89 Million | $-67.53 Million | -0.300x | +53.55% |
| 2024-12-31 | $123.51 Million | $-79.85 Million | -0.647x | -65.53% |
| 2023-12-31 | $194.10 Million | $-75.81 Million | -0.391x | -15.63% |
| 2022-12-31 | $185.29 Million | $-62.59 Million | -0.338x | +14.03% |
| 2021-12-31 | $199.13 Million | $-78.24 Million | -0.393x | -157.70% |
| 2020-12-31 | $225.88 Million | $-34.44 Million | -0.152x | +27.72% |
| 2019-12-31 | $45.52 Million | $-9.60 Million | -0.211x | -8.54% |
| 2018-12-31 | $48.31 Million | $-9.39 Million | -0.194x | +53.20% |
| 2017-12-31 | $48.68 Million | $-20.21 Million | -0.415x | -104.01% |
| 2016-12-31 | $19.46 Million | $201.51 Million | 10.355x | +5461.03% |
| 2015-12-31 | $16.65 Million | $-3.22 Million | -0.193x | +58.34% |
| 2014-12-31 | $18.27 Million | $-8.47 Million | -0.464x | +52.54% |
| 2013-12-31 | $7.34 Million | $-7.17 Million | -0.977x | -391.08% |
| 2012-12-31 | $11.67 Million | $-2.32 Million | -0.199x | +59.61% |
| 2011-12-31 | $15.85 Million | $-7.81 Million | -0.493x | +59.53% |
| 2010-12-31 | $12.21 Million | $-14.86 Million | -1.217x | +91.85% |
| 2009-12-31 | $1.88 Million | $-28.15 Million | -14.936x | -2046.03% |
| 2008-12-31 | $18.96 Million | $-13.20 Million | -0.696x | -107.07% |
| 2007-12-31 | $40.57 Million | $-13.64 Million | -0.336x | -1355.97% |
| 2006-12-31 | $57.11 Million | $1.53 Million | 0.027x | +236.37% |
| 2005-12-31 | $69.68 Million | $554.33K | 0.008x | -- |
About Altimmune Inc
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.